|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2010. CA Cancer J Clin. 61:10–29. 2011.
|
|
2
|
Meyerhardt JA, Li L, Sanoff HK, Carpenter
W IV and Schrag D: Effectiveness of bevacizumab with first-line
combination chemotherapy for Medicare patients with stage IV
colorectal cancer. J Clin Oncol. 30:608–615. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Okabe S, Fukuda T, Ishibashi K, Kojima S,
Okada S, Hatano M, Ebara M, Saisho H and Tokuhisa T: BAZF, a novel
Bcl6 homolog, functions as a transcriptional repressor. Mol Cell
Biol. 18:4235–4244. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sakashita C, Fukuda T, Okabe S, Kobayashi
H, Hirosawa S, Tokuhisa T, Miyasaka N, Miura O and Miki T: Cloning
and characterization of the human BAZF gene, a homologue of the
BCL6 oncogene. Biochem Biophys Res Commun. 291:567–573. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Oatley JM, Avarbock MR, Telaranta AI,
Fearon DT and Brinster RL: Identifying genes important for
spermatogonial stem cell self-renewal and survival. Proc Natl Acad
Sci USA. 103:9524–9529. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Manders PM, Hunter PJ, Telaranta AI, Carr
JM, Marshall JL, Carrasco M, Murakami Y, Palmowski MJ, Cerundolo V,
Kaech SM, et al: BCL6b mediates the enhanced magnitude of the
secondary response of memory CD8+ T lymphocytes. Proc Natl Acad Sci
USA. 102:7418–7425. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang H, Okada S, Hatano M, Okabe S and
Tokuhisa T: A new functional domain of Bcl6 family that recruits
histone deacetylases. Biochim Biophys Acta. 1540:188–200. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ying J, Srivastava G, Hsieh WS, Gao Z,
Murray P, Liao SK, Ambinder R and Tao Q: The stress-responsive gene
GADD45G is a functional tumor suppressor, with its response to
environmental stresses frequently disrupted epigenetically in
multiple tumors. Clin Cancer Res. 11:6442–6449. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Greipp PT, Smoley SA, Viswanatha DS,
Frederick LS, Rabe KG, Sharma RG, Slager SL, Van Dyke DL, Shanafelt
TD, Tschumper RC and Zent CS: Patients with chronic lymphocytic
leukaemia and clonal deletion of both 17p13.1 and 11q22.3 have a
very poor prognosis. Br J Haematol. 163:326–333. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xu L, Li X, Chu ES, Zhao G, Go MY, Tao Q,
Jin H, Zeng Z, Sung JJ and Yu J: Epigenetic inactivation of BCL6B,
a novel functional tumour suppressor for gastric cancer, is
associated with poor survival. Gut. 61:977–985. 2012. View Article : Google Scholar
|
|
11
|
Yang Q, Gao J, Xu L, Zeng Z, Sung JJ and
Yu J: Promoter hypermethylation of BCL6B gene is a potential plasma
DNA biomarker for gastric cancer. Biomarkers. 18:721–725. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Deng J, Han L, Dong Q, Hou Y, Xie X, Yu J,
Fan D and Hao X: The survival decrease in gastric cancer is
associated with the methylation of B-cell CLL/lymphoma 6 member B
promoter. Open Biol. 4:1400672014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang J, Dong L, Xu L, Chu ES, Chen Y, Shen
J, Li X, Wong CC, Sung JJ and Yu J: B cell CLL/lymphoma 6 member B
inhibits hepatocellular carcinoma metastases in vitro and in mice.
Cancer Lett. 355:192–200. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li X, Yu J, Brock MV, Tao Q, Herman JG,
Liang P and Guo M: Epigenetic silencing of BCL6B inactivates p53
signaling and causes human hepatocellular carcinoma cell resist to
5-FU. Oncotarget. 6:11547–11560. 2015.PubMed/NCBI
|
|
15
|
Hu S, Cao B, Zhang M, Linghu E, Zhan Q,
Brock MV, Herman JG, Mao G and Guo M: Epigenetic silencing BCL6B
induced colorectal cancer proliferation and metastasis by
inhibiting P53 signaling. Am J Cancer Res. 5:651–662.
2015.PubMed/NCBI
|
|
16
|
Franke TF: PI3K/Akt: Getting it right
matters. Oncogene. 27:6473–6488. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nicholson KM and Anderson NG: The protein
kinase B/Akt signalling pathway in human malignancy. Cell Signal.
14:381–395. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Michl P and Downward J: Mechanisms of
disease: PI3K/AKT signaling in gastrointestinal cancers. Z
Gastroenterol. 43:1133–1139. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kawauchi K, Ogasawara T, Yasuyama M,
Otsuka K and Yamada O: The PI3K/Akt pathway as a target in the
treatment of hematologic malignancies. Anticancer Agents Med Chem.
9:550–559. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Manfredi GI, Dicitore A, Gaudenzi G,
Caraglia M, Persani L and Vitale G: PI3K/Akt/mTOR signaling in
medullary thyroid cancer: A promising molecular target for cancer
therapy. Endocrine. 48:363–370. 2015. View Article : Google Scholar
|
|
21
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rychahou PG, Jackson LN, Silva SR,
Rajaraman S and Evers BM: Targeted molecular therapy of the PI3K
pathway: Therapeutic significance of PI3K subunit targeting in
colorectal carcinoma. Ann Surg. 243:833–844. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gao N, Zhang Z, Jiang BH and Shi X: Role
of PI3K/AKT/mTOR signaling in the cell cycle progression of human
prostate cancer. Biochem Biophys Res Commun. 310:1124–1132. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Song G, Ouyang G and Bao S: The activation
of AKT/PKB signaling pathway and cell survival. J Cell Mol Med.
9:592005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zang M, Zhang B, Zhang Y, Li J, Su L, Zhu
Z, Gu Q, Liu B and Yan M: CEACAM6 promotes gastric cancer invasion
and metastasis by inducing epithelial-mesenchymal transition via
PI3K/AKT signaling pathway. Plos One. 9:e1129082014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ptak A, Hoffmann M, Gruca I and Barć J:
Bisphenol A induce ovarian cancer cell migration via the MAPK and
PI3K/Akt signalling pathways. Toxicol Lett. 229:357–365. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang W, Glöckner SC, Guo M, Machida EO,
Wang DH, Easwaran H, Van Neste L, Herman JG, Schuebel KE, Watkins
DN, et al: Epigenetic inactivation of the canonical Wnt antagonist
SRY-box containing gene 17 in colorectal cancer. Cancer Res.
68:2764–2772. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ying J, Poon F, Yu J, Geng H, Wong AH, Qiu
GH, Goh HK, Rha SY, Tian L, Chan AT, et al: DLEC1 is a functional
3p22.3 tumour suppressor silenced by promoter CpG methylation in
colon and gastric cancers. Br J Cancer. 100:663–669. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hanada N, Takahata T, Zhou Q, Ye X, Sun R,
Itoh J, Ishiguro A, Kijima H, Mimura J, Itoh K, et al: Methylation
of the KEAP1 gene promoter region in human colorectal cancer. BMC
Cancer. 12:662012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Migheli F and Migliore L: Epigenetics of
colorectal cancer. Clin Genet. 81:312–318. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Conacci-Sorrell M, Zhurinsky J and
Ben-Ze'ev A: The cadherin-catenin adhesion system in signaling and
cancer. J Clin Invest. 109:987–991. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Parsons DW, Wang TL, Samuels Y, Bardelli
A, Cummins JM, DeLong L, Silliman N, Ptak J, Szabo S, Willson JK,
et al: Colorectal cancer: Mutations in a signalling pathway.
Nature. 436:7922005. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Burgering BM and Coffer PJ: Protein kinase
B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction.
Nature. 376:599–602. 1995. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ekstrand AI, Jönsson M, Lindblom A, Borg Å
and Nilbert M: Frequent alterations of the PI3K/AKT/mTOR pathways
in hereditary nonpolyposis colorectal cancer. Fam Cancer.
9:125–129. 2010. View Article : Google Scholar
|
|
35
|
Lau MT and Leung PC: The PI3K/Akt/mTOR
signaling pathway mediates insulin-like growth factor 1-induced
E-cadherin down-regulation and cell proliferation in ovarian cancer
cells. Cancer Lett. 326:191–198. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Dilly AK, Ekambaram P, Guo Y, Cai Y,
Tucker SC, Fridman R, Kandouz M and Honn KV: Platelet-type
12-lipoxygenase induces MMP9 expression and cellular invasion via
activation of PI3K/Akt/NF-κB. Int J Cancer. 133:1784–1791. 2013.
View Article : Google Scholar : PubMed/NCBI
|
